How to buy Sorrento Therapeutics stock | $10.12

Sorrento Therapeutics, Inc is a biotechnology business based in the US. Sorrento Therapeutics shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therapeutics employs 502 staff and has a trailing 12-month revenue of around USD$40 million.

How to buy shares in Sorrento Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sorrento Therapeutics. Find the stock by name or ticker symbol: SRNE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sorrento Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$10.12, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sorrento Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sorrento Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. SRNE shares summary
2. Compare share dealing platforms
3. Is SRNE stock a buy or sell?
4. Stock performance over time
5. Can I short SRNE shares?
6. Sorrento Therapeutics's financials
7. How volatile are SRNE shares?
8. Does Sorrento Therapeutics pay a dividend?
9. Have SRNE shares ever split?
10. Other common questions

Sorrento Therapeutics share price

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-03.

Latest market close	USD$10.12
52-week range	USD$1.55 - USD$19.39
50-day moving average	USD$12.0515
200-day moving average	USD$9.1686
Wall St. target price	USD$28
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.404

Buy Sorrento Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sorrento Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sorrento Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sorrento Therapeutics price performance over time

Historical closes compared with the close of $10.12 from 2021-02-25

1 week (2021-02-25)	10.12
1 month (2021-02-04)	-27.19%
3 months (2020-12-04)	26.98%
6 months (2020-09-04)	54.03%

1 year (2020-03-04)	372.90%
2 years (2019-03-04)	393.66%
3 years (2018-03-02)	40.56%
5 years (2016-03-04)	64.55%

Shorting Sorrento Therapeutics shares

There are currently 64.1 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 6.9% up from 60.0 million last month.

There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.

Sorrento Therapeutics's "short interest ratio" (SIR)

Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 27.0 million). Sorrento Therapeutics's SIR currently stands at 2.38. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 2380 shares are currently held short.

However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.23% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 230 shares are currently held short) or 0.2326% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 233 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sorrento Therapeutics.

Find out more about how you can short Sorrento Therapeutics stock.

Have Sorrento Therapeutics's shares ever split?

Sorrento Therapeutics's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.

Sorrento Therapeutics share price volatility

Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as $1.55 up to $19.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.3773. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therapeutics overview

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Frequently asked questions

• What percentage of Sorrento Therapeutics is owned by insiders or institutions?

  Currently 15.709% of Sorrento Therapeutics shares are held by insiders and 27.975% by institutions.

• How many people work for Sorrento Therapeutics?

  Latest data suggests 502 work at Sorrento Therapeutics.

• When does the fiscal year end for Sorrento Therapeutics?

  Sorrento Therapeutics's fiscal year ends in December.

• Where is Sorrento Therapeutics based?

  Sorrento Therapeutics's address is: 4955 Directors Place, San Diego, CA, United States, 92121

• What is Sorrento Therapeutics's ISIN number?

  Sorrento Therapeutics's international securities identification number is: US83587F2020

• What is Sorrento Therapeutics's CUSIP number?

  Sorrento Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74838K108